ClinicalTrials.gg
CompletedNCT05698329Updated Nov 4, 2026

Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME

A Phase 1 interventional study of AIV007 in Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Macular Edema, sponsored by AiViva BioPharma, Inc.. Completed at 6 sites in United States. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AiViva BioPharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.
Updated Nov 4, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
177th of 244
19 · median 45
Started
2023
with 10 others
Phase 1
43 of 276
3 open now
Registered
241st of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 177th largest by enrollment of the 244 interventional ones that give a count, is one of 11 that started in 2023, is one of 43 in phase 1, and was the 241st registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 21 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Read the detailed description

AIV007 is a multiple kinase inhibitor of vascular endothelial growth factor receptors (VEGFR 1, -2 \& -3); fibroblast growth factor receptors (FGFR-1, -2, -3 \& -4); and platelet-derived growth factor receptors (PDGFR-α \& β)1. Lenvatinib is the active pharmaceutical ingredient in AIV007 formulation that is FDA-approved for oral administration for patients with advanced renal cell carcinoma (RCC), differentiated thyroid cancer (DTC), unresectable hepatocellular carcinoma (HCC), and advanced endometrial carcinoma.

. AiViva BioPharma, Inc. (AiViva) has developed a novel, thermoresponsive gel suspension of AIV007 for periocular administration to form a durable depot. This monotherapy is in development for the treatment of retinal and choroidal vascular disease (i.e., neovascular age-related macular degeneration (nAMD) \& diabetic macular edema (DME)). For preclinical and clinical (AIV007-E02) studies using periocular administration, AIV007 is injected outside the eyeball and the depot forms a soft mass, referred to as posterior juxtascleral depot (PJD) placement.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Macular Edema

Browse trials for

Keywords

  • Anti-VEGF inhibitor
  • nAMD
  • Macular edema
  • DME
  • periocular
  • drug depot
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General inclusion Criteria:

  1. Male or female subjects aged 21-90 years (inclusive) at screening
  2. BCVA in the study eye at screening and baseline/Day 1: ETDRS letter score ≤ 75 and ≥ 24 (20/32 to 20/330 Snellen equivalent)
  3. Subject must have received treatment within the 24 months before screening with intravitreal (IVT) injections of an anti-VEGF agent with the last anti-VEGF injection in the study eye being at least 6 weeks (42 days) before baseline/Day 1.
  4. Subject has documentation of anti-VEGF responsiveness
  5. Subject must provide written before any study-related procedures are performed
  6. Clear ocular media and adequate pupil dilation in both eyes to permit good-quality photographic imaging

nAMD subject

  1. The active choroidal neovascularization (CNV) is confirmed by fluorescein angiography (FA; evidence of leakage)
  2. Residual intraretinal or subretinal fluid based on SD-OCT
  3. CST ≥ 300 µm as assessed by SD-OCT
  4. Total lesion size \< 10 disc areas (25.4 mm2)
  5. Absence of geographic atrophy within 200 µm of the fovea
  6. If subretinal hemorrhage is present, it must be \< 50% of the total CNV lesion and/or not involve the fovea
  7. If fibrosis is present, it must be \<50% of the total lesion area

DME subject

  1. Diagnosis of diabetes mellitus (Type 1 or Type 2)
  2. Subject has DME with central involvement (CST≥300 μm by OCT)
  3. The decrease in vision in the study eye was determined by the investigator to be primarily the result of DME

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment for nAMD or DME in the study eye other than standard-of-care anti-VEGF IVT injection, e.g., cell therapy, brachytherapy, gene therapy
  2. Uncontrolled intraocular pressure (IOP), defined as an IOP > 25 mmHg
  3. Poorly controlled diabetes mellitus defined as (HbA1c) >10% at screening visit
  4. The spherical equivalent for refractive error in the study eye of worse than 8.0 diopters of myopia (before cataract or refractive surgery) per the current prescription
  5. Any history of active bacterial, viral, fungal, or parasitic ocular or periocular infection, or intraocular inflammation in either eye within the 30 days before the screening Visit
  6. History of vitreous hemorrhage within 3 months before screening in the study eye
  7. Uncontrolled systemic disease or any other condition or therapy that would make the participant unsuitable for the study
  8. Participation in any study within 60 days before the screening visit, or planned use of an investigational product or device during the study; any exposure to a prior investigational drug product must be fully washed out (at least 5 half-lives)
  9. History of allergy or to constituents of the study treatment formulation, topical iodine, ocular antimicrobial solutions, or hypersensitivity to fluorescein
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    AIV007 low dose

    Periocular injection, low dose

    Drug: AIV007

  • Experimental
    AIV007 intermediate dose 1

    Periocular injection, intermediate dose 1

    Drug: AIV007

  • Experimental
    AIV007 intermediate dose 2

    Periocular injection, intermediate dose 2

    Drug: AIV007

  • Experimental
    AIV007 intermediate dose 3

    Periocular injection, intermediate dose 3

    Drug: AIV007

  • Experimental
    AIV007 intermediate dose 4

    Periocular injection, intermediate dose 4

    Drug: AIV007

  • Experimental
    AIV007 High dose

    Periocular injection, high dose

    Drug: AIV007

Interventions

  • DrugAIV007

    Periocular injection

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Incidence of adverse events and serious adverse events

    Time frame: Approximately 168 days

Secondary outcomes

  1. Mean change from baseline in best-corrected visual acuity (BCVA)

    Number of Early Treatment Diabetic Retinopathy Study (ETDRS) letters

    Time frame: Approximately 168 days

  2. Mean change from baseline in central subfield thickness as measured by spectral domain optical coherence tomography (SD-OCT)

    SD-OCT read by a central reading center

    Time frame: Approximately 168 days

  3. Mean time to rescue medication

    number of days to receive rescue medication

    Time frame: Approximately 168 days

07

Study locations

6 sites
  • Retina-Vitreous Associates
    Beverly Hills, California 90211, United States
  • Orange County Retina
    Santa Ana, California 92705, United States
  • Verum Research
    Eugene, Oregon 97401, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Texas Retina Associates
    Plano, Texas 75075, United States
  • Medical Center Ophthalmology
    San Antonio, Texas 78240, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2025, 24 months.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's 24 months is close to that.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2025 → Mar 2025, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Jan 26, 2023
StartActual
Mar 2, 2023
Primary completionActual
Mar 3, 2025
CompletionActual
Mar 3, 2025was Apr 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Study completion
Apr 1, 2025→Mar 3, 2025 (actual)
Nov 4, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedThe active choroidal neovascularization (CNV) is confirmed by FAfluorescein angiography (FA; evidence of leakage)
Exclusion criteria
  • EditedUncontrolled intraocular pressure (IOP), defined as an IOP > 25 mmHg
Nov 4, 2026
Title
Effect of AIV007 by Periocular Administration in Subjects withWith Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    Study completion Apr 1, 2025→Mar 3, 2025 (now actual)
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedThe active choroidal neovascularization (CNV) is confirmed by FAfluorescein angiography (FA; evidence of leakage)
    Exclusion criteria
    • EditedUncontrolled intraocular pressure (IOP), defined as an IOP > 25 mmHg
    Title Effect of AIV007 by Periocular Administration in Subjects withWith Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
    + 5 other changes: verification date, oversight details, description, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05698329
Lead sponsor
AiViva BioPharma, Inc.
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Mar 2, 2023
Primary completion
Mar 3, 2025
Completion
Mar 3, 2025
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AIV007

Start the discussion